Immunic(IMUX) Prnewswire·2025-02-26 11:30Core Insights - Immunic, Inc. presented data on its lead asset, vidofludimus calcium, at the ACTRIMS Forum 2025, highlighting its potential as a treatment for multiple sclerosis [1][2] - The company expects top-line data from the Phase 2 CALLIPER trial in progressive multiple sclerosis to be released in April 2025, which will provide insights into the drug's effects on a non-active patient population [2][4] Company Overview - Immunic, Inc. is a biotechnology company focused on developing orally administered small molecule therapies for chronic inflammatory and autoimmune diseases [1][10] - Vidofludimus calcium is currently in Phase 3 and Phase 2 clinical trials for relapsing and progressive multiple sclerosis, respectively, and has shown therapeutic activity in previous trials [10] Drug Mechanism and Research Findings - Vidofludimus calcium acts as a selective immune modulator by activating the neuroprotective transcription factor Nurr1, which is associated with direct neuroprotective effects [9] - The drug also selectively inhibits dihydroorotate dehydrogenase (DHODH), impacting overactive immune cells and providing anti-inflammatory and anti-viral effects [9] - Preclinical studies indicate that vidofludimus calcium reduces neuronal loss and injury by decreasing microglial activation, suggesting its neuroprotective potential [4][9] Presentation Details - Two poster presentations at the ACTRIMS Forum will cover the baseline characteristics of patients in the CALLIPER trial and the neuroprotective function of vidofludimus calcium [8][9] - The first poster will analyze patient characteristics across major clinical trials in progressive multiple sclerosis, while the second will present evidence of the drug's neuroprotective effects [8][9]